Table 3.
Univariate and multivariate analyses of progression‐free and overall survival for performance status of 0–1
| Characteristic | Subgroups | HR for PFS (95% CI) | HR for OS (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate | P‐value | Multivariate | P‐value | Univariate | P‐value | Multivariate | P‐value | ||
| Age | <65 years/≥65 years | 1.20 (0.83–1.70) | 0.30 | 0.84 (0.53–1.28) | 0.43 | ||||
| Sex | Male/Female | 1.02 (0.72–1.42) | 0.89 | 1.33 (0.88–2.00) | 0.16 | ||||
| Smoking status | Ever/never | 1.10 (0.78–1.54) | 0.56 | 1.70 (1.13–2.55) | 0.01 | 1.61 (1.07–2.42) | 0.02 | ||
| Line of EGFR‐TKI | 1/≥2 | 1.08 (0.73–1.63) | 0.69 | 1.11 (0.69–1.84) | 0.66 | ||||
| EGFR‐TKI | Gefitinib or erlotinib/afatinib | 1.59 (1.04–2.56) | 0.03 | 1.69 (1.10–2.73) | 0.01 | 1.45 (0.81–2.83) | 0.21 | ||
| EGFR mutation | Ex19del or L858R/other | 0.55 (0.27–1.31) | 0.16 | 0.46 (0.20–1.33) | 0.14 | ||||
| T790M mutation | Yes/no or unknown | 1.03 (0.59–1.69) | 0.88 | 0.47 (0.19–0.95) | 0.03 | 0.52 (0.21–1.05) | 0.07 | ||
| GPS score | 2/0–1 | 2.24 (1.13–3.98) | 0.02 | 2.51 (1.26–4.49) | 0.01 | 3.42 (1.58–6.58) | <0.01 | 3.00 (1.38–5.78) | <0.01 |
CI, confidence interval; EGFR, epidermal growth factor receptor; GPS, Glasgow prognostic score; HR, hazard ratio; OS, overall survival; PFS, progression‐free survival; TKI, tyrosine kinase inhibitor.